Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mintie Pritchard

Physician Assistant, Medical Beckley, WV Physician Assistant

NPI 1396073656 CMS profile 10734013

230 George St Ste 2, Beckley, WV 25801

Open in the dashboard

General payments

$6,563

420 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mintie Pritchard of Beckley, WV is reported in the CMS Open Payments database as having received $6,563 across 420 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $618 36
2024 General $1,376 78
2023 General $1,424 92
2022 General $1,529 90
2021 General $1,616 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mintie Pritchard
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Mintie Pritchard were reported at $618. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Mintie Pritchard Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,616 $156 $41–$563 $132
2022 $1,529 $185 $55–$649 $149
2023 $1,424 $199 $58–$717 $160
2024 $1,376 $206 $62–$740 $164
2025 $618 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,439 115 payments
  2. Novo Nordisk Inc $924 56 payments
  3. Lilly USA, LLC $821 53 payments
  4. AstraZeneca Pharmaceuticals LP $383 22 payments
  5. Shield Therapeutics Inc $376 13 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $316 20 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $314 21 payments
  8. Abbott Laboratories $267 15 payments
  9. Esperion Therapeutics, Inc. $218 21 payments
  10. Amgen Inc. $193 13 payments
  11. Other $1,312 71 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,551 419 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $751 45 payments
  2. RYBELSUS $625 41 payments
  3. UBRELVY $561 42 payments
  4. VRAYLAR $496 50 payments
  5. QULIPTA $386 24 payments
  6. ACCRUFER $376 13 payments
  7. JARDIANCE $363 21 payments
  8. FARXIGA $319 20 payments
  9. MOUNJARO $302 23 payments
  10. XIFAXAN $295 20 payments
  11. Other $4,263 262 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 178 drugs

Part D claims

9,830

Median for Physician Assistant: 241

Drug cost

$976,312

Median for Physician Assistant: $4,110

Branded share of claims

20.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 94 $158,778
Mounjaro Tirzepatide Brand 111 $151,084
Eliquis Apixaban Brand 147 $135,841
Jardiance Empagliflozin Brand 82 $107,855
Tresiba Flextouch U-200 Insulin Degludec Brand 54 $37,545
Entresto Sacubitril/Valsartan Brand 24 $33,290
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 34 $28,435
Xarelto Rivaroxaban Brand 23 $25,151
Linzess Linaclotide Brand 33 $24,817
Farxiga Dapagliflozin Propanediol Brand 21 $22,734

The 10 drugs with the highest cost, of 178 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$56,455

Of which drugs: $2,137

Medicare patients

218

Average age 72

Services billed

1,816

161 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 40%
Ischemic heart disease 30%
Depression 22%
Osteoporosis 19%
Chronic kidney disease 17%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 49 49 $1,073
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 29 59 $56
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 45 564 $45
Injection, ketorolac tromethamine, per 15 mg J1885 Office 17 76 $37
Injection, ceftriaxone sodium, per 250 mg J0696 Office 19 88 $31

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Lilly USA, LLC $58
  • Boehringer Ingelheim Pharmaceuticals, Inc. $41
$99 82 —
Ozempic
  • Novo Nordisk Inc $87
$87 94 —
QULIPTA
  • AbbVie, Inc. $75
$75 — —
VRAYLAR
  • AbbVie, Inc. $75
$75 — —
MOUNJARO
  • Lilly USA, LLC $74
$74 111 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

420 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record